Echosens technology used for liver fibrosis study

By staff writers

January 22, 2020 -- Ultrasound technology developer Echosens is supplying its FibroScan test to the Fatty Liver Foundation as part of a research study designed to screen for undetected nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

FibroScan is being used as part of the Screening for Undiagnosed NAFLD and NASH (SUNN) study, which is designed to identify risk factors in individuals who have advancing but asymptomatic liver disease but have not been diagnosed by a physician, instead choosing to self-select for screening. The foundation has completed the patient recruitment phase of the SUNN study and plans to publish the study's results.

FibroScan is a five-minute test for NAFLD that can be performed at the point of care to help physicians detect, monitor, and prevent liver disease in asymptomatic individuals who may be at high risk.

Copyright © 2020

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking